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Abstract
Background: Early diagnosis of HIV in infants provides a critical opportunity to strengthen follow-up of HIV-
exposed children and assure early access to antiretroviral (ARV) treatment for infected children. This study describes
findings from an Early Infant Diagnosis (EID) program and the effectiveness of a prevention of mother-to-child
transmission (PMTCT) intervention in six health facilities in Cross-River and Akwa-Ibom states, south-south Nigeria.
Methods: This was a retrospective study. Records of 702 perinatally exposed babies aged six weeks to 18 months
who had a DNA PCR test between November 2007 and July 2009 were reviewed. Details of the ARV regimen
received to prevent mother-to-child transmission (MTCT), breastfeeding choices, HIV test results, turn around time
(TAT) for results and post test ART enrolment status of the babies were analysed.
Results: Two-thirds of mother-baby pairs received ARVs and 560 (80%) babies had ever been breastfed.
Transmission rates for mother-baby pairs who received ARVs for PMTCT was 4.8% (CI 1.3, 8.3) at zero to six weeks
of age compared to 19.5% (CI 3.0, 35.5) when neither baby nor mother received an intervention. Regardless of
intervention, the transmission rates for babies aged six weeks to six months who had mixed feeding was 25.6% (CI
29.5, 47.1) whereas the transmission rates for those who were exclusively breastfed was 11.8% (CI 5.4, 18.1). Vertical
transmission of HIV was eight times (AOR 7.8, CI: 4.52-13.19) more likely in the sub-group of mother-baby pairs
who did not receive ARVS compared with mother-baby pairs that did receive ARVs. The median TAT for test results
was 47 days (IQR: 35-58). A follow-up of 125 HIV positive babies found that 31 (25%) were enrolled into a
paediatric ART program, nine (7%) were known to have died before the return of their DNA PCR results, and 85
(67%) could not be traced and were presumed to be lost-to-follow-up.
Conclusion: Reduction of MTCT of HIV is possible with effective PMTCT interventions, including improved access
to ARVs for PMTCT and appropriate infant feeding practices. Loss to follow up of HIV exposed infants is a challenge
and requires strategies to enhance retention.
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Background
Mother-to-child transmission (MTCT) of HIV is one of
the biggest challenges of the HIV/AIDS pandemic espe-
cially in resource constrained settings [1,2]. Africa has
the highest burden of the disease accounting for about
90 percent of paediatric HIV infections [3]. In 2009
approximately 370,000 children became infected with
HIV globally; most of these infections occurred through
mother-to-child transmission (MTCT). In the absence
of any intervention, the combined risk of mother-to-
child transmission of HIV in utero and intra-partum is
15-30 percent. Breastfeeding increases the risk to 20-45
percent [4,5]. Evidence-based research suggests that
antiretroviral (ARV) drugs given to pregnant women
and their newborn babies reduce the risk of mother-to-
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any medium, provided the original work is properly cited.child transmission [6-8]. If untreated, HIV infections in
children is associated with very high mortality rates
[9,10]. A pooled analysis of outcomes of HIV infected
infants in sub-Saharan Africa found that 35 percent and
52 percent of HIV-infected children die by age one and
two respectively [9].
The empirical evidence of the effectiveness of PMTCT
interventions based on short course treatment with anti-
retroviral drugs has been clearly demonstrated in large
scale programs integrated into routine antenatal and
obstetrics setting in South Africa and Zambia [11-13].
Early Infant Diagnosis (EID) is part of the infant,
maternal, neonatal and child health service package of
PMTCT interventions. The DNA Polymerase Chain
Reaction (PCR) used for EID tests directly for HIV
DNA rather than the HIV antibody and provides defini-
tive diagnosis in children less than 18 months of age
[14].
EID makes it possible for HIV-exposed infants to
receive early clinical evaluation, prophylaxis for opportu-
nistic infections and antiretroviral therapy (ART) if indi-
cated [15]. Furthermore, a review of HIV test results in
an EID program provides a unique opportunity for eval-
uating the success of the PMTCT program [11].
Nigeria is responsible for 30 percent of the global bur-
den of MTCT of HIV, and is one of the 22 focus coun-
tries of the Global Plan to Eliminate MTCT. Though
the Government of Nigeria is intensifying PMTCT pro-
gram efforts to achieve this goal, evidence on the effec-
tiveness of PMTCT interventions or their bottlenecks
remains limited [16].
This study examined an Early Infant Diagnosis pro-
gram in six health facilities in Cross-River and Akwa-
Ibom states in South-South Nigeria using routine pro-
gram data with the aim of evaluating the effectiveness of
PMTCT interventions in reducing vertical transmission
of HIV and also highlights the challenges of continuum
of care for HIV positive babies.
Methods
Study design and population
This was a retrospective study. The study population
comprised all perinatally HIV exposed children aged six
weeks to 18 months who had Dried Blood Spot (DBS)
samples taken for a DNA PCR test between November
2007 and July 2009, and for whom a complete set of
records were available.
Study context and site selection
The Government of Nigeria commenced a National EID
program in February 2007 [17]. As part of the second
phase of the pilot, an EID program was established in
six health facilities in Cross River and Akwa Ibom states,
South-South Nigeria in November 2007. These sites
were supported by the Global HIV/AIDS Initiative in
Nigeria (GHAIN), a PEPFAR-funded HIV/AIDS pro-
gramme implemented by a consortium led by FHI 360.
The facilities also had PMTCT and ART programs
which were established with support from GHAIN.
Pregnant women registered for antenatal care (ANC)
in the study facilities at 14 weeks of gestation and
made repeated visits at frequencies determined by their
care provider until delivery. During the first ANC visit,
all pregnant women received HIV testing and counsel-
ing. Following the National PMTCT guidelines at the
time of the study [18], pregnant women who tested
positive for HIV were evaluated for clinical and immu-
nological eligibility for the commencement of ART.
Eligible clients began a first line highly active antiretro-
viral therapy (HAART) regimen which consisted of a
cocktail of either Zidovudine (AZT) or Stavudine
(D4T) plus Lamivudine (3TC) plus either Nevirapine
(NVP) or Efavirenz (EFZ). The choice of the specific
regimen was guided by the clients’ clinical condition
and presence of contra-indication to any of the drug
options. All clients underwent a series of adherence
counseling before initiating HAART and on every
occasion of a drug refill. HIV positive pregnant women
who did not meet the criteria for initiating HAART
were placed on HIV chemoprophylaxis, which com-
prised zidovudine (AZT) beginning at 28 weeks of
gestation and administration of single dose nevirapine
(sdNVP) during labour. Pregnant women starting pro-
phylaxis at 33 weeks of gestation were given zidovudine
(AZT) plus lamivudine (3TC) and sdNVP taken during
labour. Women newly diagnosed for HIV during labour
received sdNVP alone.
Babies born to HIV positive women received sdNVP
within the first three days of life and AZT for six weeks.
The HIV-exposed infants were thereafter screened for
HIV according to the National EID algorithm which sti-
pulates that a DNA PCR test should be carried out on
all HIV-exposed infants at age six weeks. Following the
clinic visit for HIV screening, HIV-exposed infants were
initiated on cotrimoxazole prophylaxis and their care-
givers advised to return in four weeks to receive the
DNA PCR test results. The DBS samples collected were
couriered to a DNA PCR testing facility (University of
Benin Teaching Hospital) located over 600 kilometers
from each of the health facilities. The test was carried
out using the GeneAmp PCR System 9700 (Perkin-
Elmer, Norwalk, Conn, USA). On return of the test
results to the facility, caregivers of infants with a positive
HIV result were counselled to enrol the infant into HIV
care and treatment services, while those who breastfed
and whose babies have a negative HIV results were
advised to return six weeks after the complete cessation
of breastfeeding for a repeat DNA PCR test.
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This study was based on a review of data routinely col-
lected at six GHAIN-supported EID sites in Cross River
and Akwa Ibom states in Nigeria. Routine service data
was extracted from structured national data collection
tools and entered into a Microsoft Excel spreadsheet
®
designed for data entry. These national tools from
which the data for the analysis were drawn include 1)
the PCR request and result forms; 2) the EID register
which contain information on the baseline characteris-
tics of HIV-exposed babies, type of ARV chemoprophy-
laxis received by the mother and the baby, breastfeeding
practices, turnaround time and outcome of the DNA
PCR test; and 3) the pre-ART register which contains
information of HIV positive babies enrolled in HIV care
and treatment.
Data analysis
Data entered into the Microsoft Excel spreadsheet
® was
cleaned and checked for consistency. The cleaned data
was exported to STATA version 10.0 (Stata Corpora-
tion, College Station, TX) for data management and
further statistical analysis. Frequency counts were per-
formed to assess completeness of all variables. The
DNA PCR result was the major outcome variable in this
study and was determined for mother-baby pairs
according to ARV prophylaxis received for PMTCT and
infant feeding methods. The age-specific transmission
rates along with the 95% confidence intervals were esti-
mated for each sub-population. Correlates of mother-to-
child transmission of HIV were assessed by multivari-
able logistic regression. Hosmer and Lemeshow test was
used to check for how well the model fit. All tests were
two-sided and statistical significance was set at p value
< 0.05. From these models, we estimated odds ratios
along with 95% confidence intervals, separately for each
age group. In addition infants with a positive PCR result
were categorized according to their post test ART enrol-
ment status. Differences in proportions were tested
using Chi-square test. Fisher’s exact test was used to
capture associations among categorical variables for fre-
quencies less than 5. The turn around time (TAT) for
processing the DBS sample, defined as time (in days)
between DBS sample collection and return of DNA PCR
results to the facility was described using summary sta-
tistics (medians and inter-quartile ranges). Differences in
median were tested using median test.
Ethical considerations
The study was approved by FHI 360’s Protection of
Human Subjects Committee, North Carolina, USA, and
the National Health Research and Ethics Committee
(NHREC) Abuja, Nigeria.
Results
Between November 2007 and July 2009, the DBS sam-
ples of 714 HIV exposed babies were sent for their first
DNA PCR test. Of these 702 babies were included in
the analysis and twelve babies were excluded from the
study due to data incompleteness.
Baseline characteristics
Over half (n = 369) of the study population were males.
T h em e d i a na g ea tt h et i m eo fD B Ss a m p l ec o l l e c t i o n
was 13 weeks (Inter-quartile range- 6.5 to 30.5); 70.9%
(n = 498) of samples were taken from babies at the age
of six weeks or older. Regarding location of DBS sample
collection, sizeable proportions (45.9%) of babies were
tested in rural facilities. Over one-third of mothers and
babies respectively did not receive any ARV medication
for preventing mother-to-child transmission of HIV. In
relation to infant feeding choices, the vast majority of
mothers (79.8%) reported that they breastfed. In particu-
lar, 255 (36.3%) reported exclusive breastfeeding and
305 (43.5%) reported mixed feeding (Table 1).
Table 1 Baseline characteristics of babies enrolled in the
study (N = 702)
Characteristics Number
(%)
Gender
Male 369 (52.5)
Female 333 (47.5)
Age at testing
≤ 6 weeks 204 (29.1)
6 weeks to 6 months 311 (44.3)
6- 18 months 187 (26.6)
Maternal ARV
HAART 220 (31.3)
AZT + 3TC & single dose NVP in labour 55 (7.8)
AZT & single dose NVP in labour 144 (20.5)
Single dose NVP in labour 13 (1.8)
None 270 (38.5)
Infant ARV
Single dose NVP at birth plus AZT for 4 weeks 434 (61.8)
None 268 (38.2)
Feeding methods reported at the time of 1
st PCR
testing
Replacement 142 (20.2)
Exclusive breastfeeding 255 (36.3)
Mixed feeding 305 (43.5)
Facility
Rural 322 (45.9)
Urban 380 (54.1)
* Median age 13 weeks (IQR 6.5 to 30.5)
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Analysis of the DNA PCR test results showed that,
regardless of infant feeding choice, the transmission
rates when both mother and baby received a form of
chemoprophylaxis for PMTCT was 4.8% (CI 1.3, 8.3) at
zero to six weeks of age and 6.6% (CI 3.0, 10.3) at age
six weeks to six months. When neither baby nor mother
received an intervention, the transmission rates at age
zero to six weeks and six weeks to six months was
19.5% (CI 3.0, 35.5) and 39.8% (CI 29.7, 50.0), respec-
tively. Regardless of chemoprophylaxis, babies who were
exclusively breastfed had a transmission rate of 2.7% (CI
0.1, 5.7) at six weeks and 11.8% (CI 5.4, 18.1) from six
weeks to six months. Transmission rates among babies
whose mothers practised mixed feeding was 13.4% (CI
3.8, 23.1) for babies aged zero to six weeks and 25.6%
(CI 18.1, 33.1) for babies aged six weeks to six months
(Table 2).
Risk of transmission
The unadjusted odds ratio (OR) of MTCT of HIV was
11 times (95% C.I: 6.78-18.35) higher among mother-
baby pairs where neither mother nor baby received any
ARV compared to mother-baby pairs where both
mother and baby received a minimum ARV intervention
for PMTCT. When adjusted for the impact of variables
such as the sex of the baby, age at first PCR testing, and
infant feeding choices, these mother-baby pairs were
found to be eight times more likely to transmit HIV
infection from mother to baby when compared with
babies whose mothers received chemoprophylaxis for
PMTCT (AOR 7.76, 95% CI:3.06-10.55). Also from the
multivariate analysis, babies who were tested via DNA
PCR for the first time between the age of six months
to18 months were approximately four times more likely
to be infected with HIV than those tested at six weeks
of age or less (AOR 3.77, 95% CI: 1.63-8.71) (Table 3).
Turnaround time (TAT)
The median turnaround time (TAT) for processing of
DBS samples was 47 days (IQR: 35-58). The median
turnaround time in rural settings was 57 days compared
to 40 days in urban locations (p < 0.01) (Figure 1).
Referral to care and treatment
In examining the post test ART enrolment status among
the 125 infants with a positive PCR test result, it was
observed that 31 babies (25%) were enrolled into a pae-
diatric ART care and treatment program. Nine babies
(7%) were known to have died before their DNA PCR
results were returned to the facility while records of
ART enrolment for the remaining babies (n = 87, 67%)
were not located in the six hospitals involved in the
study.
Discussion
For any PMTCT programme to effectively prevent verti-
cal transmission of HIV between mother and baby, a
pregnant woman must successfully follow the PMTCT
cascade beginning with acceptance of HIV counselling
and testing to receiving ARV prophylaxis (if HIV posi-
tive) and safe infant feeding practices. Uptake of services
provided in this cascade has been shown to be feasible
in resource limited settings by studies conducted in
Zambia and Ivory Coast where more than 80% of ANC
attendees accepted the HIV test and a majority of the
HIV positive women commenced ARV prophylaxis even
though there were reports of patient attrition between
the testing for HIV and commencement of ARV pro-
phylaxis for PMTCT [19,20]. In this study, roughly one-
third of the mother-baby pairs did not receive any form
of chemoprophylaxis for PMTCT. Patient attrition
coupled with a relatively lower ANC attendance rate,
58% in Nigeria [21], is likely to contribute to the subop-
timal uptake of ARV prophylaxis for PMTCT observed
in this study.
Table 2 Age-specific transmission rates by pharmacologic intervention and infant feeding status
Variable Number 0-6 weeks
Transmission
Rate (95% CI)
6 wks-6 months
Transmission
Rate (95% CI)
6-18 months
Transmission
Rate (95% CI)
Pharmacologic Intervention received
Mother and Baby 390 4.8 (1.3, 8.3) 6.6 (3.0, 10.3) 6.4 (0.1, 12.5)
Either Mother or Baby 86 9.3 (1.3, 20.1) 10.8 (3.1, 21.3) 11.7 (5.3,28)
Neither mother nor baby 226 19.5 (3.0, 35.5) 39.8 (29.7, 50.0) 47.7 (38.0, 57.3)
Infant feeding status
Replacement/Formula 142 12.1(1.7, 22.6) 9.2(2.6,15.9) 12.0(1.7,25.7)
Exclusive breastfeeding 255 2.7 (0.1,5.7) 11.8(5.4,18.1) 19.1(6.7,31.4)
Mixed feeding 305 13.4 (3.8,23.1) 25.6(18.1,33.1) 38.3(29.5,47.1)
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between the ages of zero and six weeks where both
mother and baby received a pharmacological interven-
tion for PMTCT, and 20% where neither mother nor
baby received ARVs, indicates that PMTCT interven-
tions are effective in a resource-limited program setting.
These findings compare reasonably with related studies
on HIV transmission rates in PMTCT program settings.
In Zambia, it was observed that the transmission rates
among babies between zero and six weeks old for the
two categories of mother-baby pairs mentioned above
were 6.5% and 20.9%, respectively [13]. Similarly a study
i nS o u t hA f r i c ab yM n y a n ie ta lr e c o r d e da no v e r a l l
transmission rate of 5.8% for HIV exposed babies
between four and six weeks of age, where both mother
and baby received some form of ARVs for PMTCT [22].
In our study, over 80% of the exposed babies screened
for HIV were breastfed. This finding is consistent with a
related study in Zambia which showed that about 84%
of HIV exposed infants whose records were reviewed
had ever been breastfed [23]. In addition, our analysis
indicated that regardless of pharmacological intervention
received by the mother-baby pairs, there was an increase
in the age-specific transmission rates for the sub-popu-
lation of babies who were exclusively breastfed and for
those who had mixed feeding. On the other hand, the
age-specific HIV transmission rates of babies who were
formula fed showed minor changes over time. Prolonged
exposure to breastfeeding is likely to have affected HIV
transmission rates for babies taking the DNA PCR test
at a later date compared with those who had the test at
six weeks. Moreover, the observed age specific transmis-
sion rates in this study were considerably higher for
babies who had mixed feeding compared with those
who were exclusively breastfed; this suggests that exclu-
sive breastfeeding is safer than mixed feeding as a feed-
ing option for HIV exposed infants. This finding is
consistent with evidence from the ZVITAMBO project
in Zimbabwe, which demonstrated that compared with
early breastfeeding, early mixed feeding was associated
with a four-fold risk of HIV transmission at six months
of age for HIV-exposed babies who had previously
tested negative at six weeks of age [24].
The 2010, WHO guidelines on HIV and infant feeding
recommend that, provided the mother and/or baby is
receiving ARVs for their health or as prophylaxis, exclu-
sive breastfeeding should be practiced by HIV-infected
mothers for the first six months of life. After the six
month period, complimentary feeding should be intro-
duced while continuing with breastfeeding for up to 12
months of age unless replacement feeding is acceptable,
feasible, affordable, sustainable and safe for them and
their infants before that time [25]. The PMTCT guide-
lines in Nigeria endorses the WHO guidelines on infant
feeding, however the reality is that pregnant women
who test positive face a difficult decision about how to
Table 3 Odds ratio of mother to child transmission (N = 702)
Variable Unadjusted OR(95% C.I) P-value Adjusted OR(95% C.I) p-value
Gender
Female 1 0.21 1 0.17
Male 1.28(0.87-1.89) 1.36 (0.88-2.12)
Age at 1
st PCR test
≤ 6 weeks 1 1
6 weeks-6 months 5.58 (2.61-11.95) < 0.01 1.87 (1.73-8.65) < 0.01
6-18 months 10.18 (4.69-22.06) < 0.01 3.77 (1.63-8.71) < 0.01
Facility location
Urban 1 1
Rural 1.03 (0.70-1.51) 0.90 1.02 (0.65-1.60) 0.93
Pharmacologic
Intervention
Mother & baby 1 1
Mother only 1.68 (0.55-5.11) 0.36 1.54 (0.49-4.84) 0.46
Baby only 2.05 (0.74-5.68) 0.17 1.98 (0.69-5.65) 0.20
None 11.16 (6.78-18.35) < 0.01 7.76 (4.49-13.49) < 0.01
Infant feeding choices
reported at the time of 1
st
PCR test
Replacement 1 1
Exclusive breastfeeding 0.84 (0.42-1.67) 0.62 0.95 (0.44-2.04) 0.90
Mixed feeding 3.38 (1.87-6.10) < 0.01 1.51 (0.77-2.95) 0.23
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proper feeding counselling support and the influence of
family members of culturally and socially accepted feed-
ing methods. This ultimately results in improper infant
feeding practices as demonstrated by the high rate of
mixed feeding practiced by the HIV positive mothers in
this study. Accurate information, clear infant feeding
guidance, and ongoing support by healthcare workers
and family members will help HIV positive mothers suc-
ceed with their chosen strategies.
Early diagnosis of HIV in infants provides a critical
opportunity to strengthen follow-up of HIV-exposed
children and initiate early treatment for those who are
HIV infected. If untreated, HIV infection in children is
associated with very high mortality rates. The children
with HIV early antiretroviral (CHER) study carried out
in South Africa showed that early diagnosis and initia-
tion of antiretroviral treatment reduces early infant mor-
tality and HIV progression by 76% and 75% respectively
[26]. The national PMTCT guidelines in Nigeria stipu-
late that the first DNA PCR test should be conducted at
six weeks of age for all HIV exposed infants [18]. How-
ever, we observed in our study that over 70% of the
infants came for the DBS test after six weeks. While
acknowledging that the launch of the EID program in
these facilities initially resulted in backlog testing of
many older age HIV exposed infants, over time it was
still observed that majority of HIV exposed infants took
the DNA PCR test at ages well over six weeks as stipu-
lated in the PMTCT guidelines. Conducting the DNA
PCR tests for early infant diagnosis at six weeks as out-
lined in the guidelines will offer the health providers the
opportunity to strengthen infant feeding counseling pro-
vided to the mothers in order to reduce post-natal
transmission of HIV.
EID also makes it possible for HIV-exposed infants to
receive an early clinical evaluation and be linked to ART
care. The finding that only 25% of the 125 babies that
tested positive in our study had established evidence of
enrolment for paediatric ART at any of the 6 study sites
is a cause for concern. The majority of HIV positive
babies were not traceable and presumed to be lost to
Figure 1 Box-plot showing median turnaround time (days) of DBS, and by location of facility.
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rates in untreated HIV positive infants [10,26], it is rea-
sonable to assume that many of the children lost to fol-
low up had died. However, it was not possible in this
study to establish how many babies among those lost to
follow up had died. Related studies done in western
Malawi also reported high loss to follow up rates for
HIV exposed babies and their mothers [27].
Improved client tracking and strengthening the link
between the PMTCT, EID and the paediatric ART,
coupled with proper and effective counselling of the
mothers of HIV-exposed babies before and after the
DNA PCR test, will increase the likelihood of enrolling
and retaining HIV-exposed babies in ART programs.
One model which can be used to improve follow-up for
these babies is an integration of HIV-exposed infant fol-
low-up with routine childhood immunisation services.
This model is being piloted in Rwanda and preliminary
results appear very promising [28]. Expanding the avail-
ability of PMTCT services in Primary Healthcare Cen-
tres (PHCs) by enabling access to CD4 count test
through a ‘hub and spoke’ laboratory referral system
and the provision of short course ARVs for PMTCT at
PHCs is an option that is worth exploring. The feasibil-
ity of this strategy has been demonstrated in Zambia
even though completion of the CD4 count assessment
at the PHCs remains a challenge [29]. The proposed
strategy also has the potential to minimize patient attri-
tion as PHCs are generally more accessible to patients.
The delay in establishing a diagnosis is another factor
that likely contributed to the high attrition rate observed
in this study. Though the threshold turnaround time
(TAT) for the return of lab results to the DBS collection
centers in the national EID program is 28 days, in this
study the median TAT for processing of DBS samples
was almost double this figure (47 days). A shorter TAT
will minimise the frustration and anxiety caregivers face
while waiting for the HIV results. This will ultimately
reduce loss to follow up and provide an opportunity for
early initiation for ART.
The limitations to our study include the purposive
nature of the selection of sites that offered EID services
in the two states where the study was carried out. In
addition, use of facility based records may have led to
selection bias (i.e., study population included those who
sought services at facilities). These limitations affected
our ability to generalize the findings of this study. Addi-
tionally, some findings have limited statistical signifi-
cance due to a limited sample size. Furthermore, we
acknowledge that our analysis would have been
strengthened by including variables such as baseline
CD4 counts and clinical staging, however, the selection
of the variables included in our analysis was guided (and
t h u sl i m i t e d )b yw h a tw ew e r ea b l et oo b t a i nf r o mt h e
national PMTCT data collection tools used and main-
tained at the study sites.
Conclusion
The findings of this study demonstrate that reduction in
maternal-to-child transmission of HIV is possible with
effective PMTCT intervention. Increase in the uptake of
chemoprophylaxis and ensuring appropriate infant feed-
ing practices is critical in reducing vertical transmission
of HIV. Strategies to address programmatic challenges
of long turnaround time, effective referrals and linkage
to care are essential. PMTCT programs with EID should
be encouraged to conduct similar analyses to determine
the effectiveness and bottlenecks in their interventions.
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